| UHC Surest Medical and Drug | Minimally Invasive Spine Surgery Procedures – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Skin and Soft Tissue Substitutes – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tepezza® (Teprotumumab-Trbw) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tezspire® (Tezepelumab-Ekko) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Total Artificial Disc Replacement for the Spine – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| Medicare NCD | NCD 210.13 - Screening for Hepatitis C Virus (HCV) in Adults | 2026-02-01 |
| Ambetter Health Florida Clinical | Applied Behavior Analysis | 2026-02-01 |
| Ambetter Health Florida Clinical | Bariatric Surgery | 2026-02-01 |
| Ambetter Health Florida Clinical | Donor Lymphocyte Infusion | 2026-02-01 |